Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Istituti Clinici Scientifici Maugeri SpA

Reviewed by TrialFinderData Editorial Team · Updated

9 clinical trials · 9 recruiting · OTHER

Istituti Clinici Scientifici Maugeri SpA has 9 clinical trials registered on ClinicalTrials.gov, with 9 actively recruiting participants. The trials listed below cover 12 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Istituti Clinici Scientifici Maugeri SpA\'s Trial Portfolio

Istituti Clinici Scientifici Maugeri SpA is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

9 of Istituti Clinici Scientifici Maugeri SpA's 9 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Istituti Clinici Scientifici Maugeri SpA's research footprint spans Multiple Sclerosis (2 trials), Differentiated Thyroid Cancer (1), and Parkinson Disease (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Istituti Clinici Scientifici Maugeri SpA's portfolio at 78% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Istituti Clinici Scientifici Maugeri SpA

RECRUITINGPhase 2NCT05852223

Pembrolizumab in High-risk Thyroid Cancer

This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 251 location
Differentiated Thyroid Cancer
RECRUITINGNCT05748015

Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis

The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 602 locations
Multiple Sclerosis
RECRUITINGNCT04876339

Sonification Techniques for Gait Training

Music therapy is widely used in relational and rehabilitation settings. In addition to Neurologic Music Therapy and other music-based techniques, "sonification" approaches were...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 1201 location
Parkinson DiseaseStrokeMultiple Sclerosis
RECRUITINGNCT05747937

Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS

The goal of this interventional non-pharmacological study is to evaluate, using a multimodal approach, the progression of autonomic and sensory involvement in in amyotrophic...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 1002 locations
Amyotrophic Lateral Sclerosis
RECRUITINGNCT06920784

Prismatic Adaptation in Cognitive Rehabilitation

The study aims to evaluate the effects of prismatic adaptation and then of a novel rehabilitation protocol that combines PA and Serious Games on cognitive and behavioural deficits...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 505 locations
Traumatic Brain Injury
RECRUITINGNCT07387185

AI System for Detection and Characterization of Chronic Enteropathies

Coeliac disease (CD) is an immune-mediated enteropathy leading to small intestinal mucosal atrophy. Diagnosis relies on serology and duodenal biopsies, but it can be complicated...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 3801 location
Celiac DiseaseSmall Bowel Mucosal Atrophy or LesionsNon-celiac Enteropathies
RECRUITINGNCT05720780

Rehabilitation Training With Music-support & Exercise Tolerance in COPD and CRF Patients.

Therapeutic-rehabilitative interventions supported by music can be considered important resources in many clinical contexts. Some studies report the improvement of psychological...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 1566 locations
COPD
RECRUITINGNCT03799354

Study on Impact of Maximal Strength Training in Patients With COPD

In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 201 location
Chronic Obstructive Pulmonary Disease
RECRUITINGNCT07302425

High-intensity Resistance Training in Post-exacerbation COPD

After a COPD exacerbation, many individuals experience severe weakness in the leg muscles, especially the quadriceps. This weakness can make daily activities difficult and slow...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 641 location
COPD Exacerbation

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Istituti Clinici Scientifici Maugeri SpA have on ClinicalTrials.gov?

Istituti Clinici Scientifici Maugeri SpA has 9 clinical trials registered on the federal ClinicalTrials.gov registry, of which 9 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Istituti Clinici Scientifici Maugeri SpA study?

Istituti Clinici Scientifici Maugeri SpA's registered trials cover 12 conditions on ClinicalTrials.gov, led by Multiple Sclerosis (2 trials), Differentiated Thyroid Cancer (1 trial), Parkinson Disease (1 trial), Stroke (1 trial), Amyotrophic Lateral Sclerosis (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Istituti Clinici Scientifici Maugeri SpA clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 9 trials tracked for Istituti Clinici Scientifici Maugeri SpA.